Lake Street analyst Frank Takkinen reiterated a Buy rating on LENSAR (LNSR – Research Report) today and set a price target of $8.00. The company’s shares closed last Friday at $3.26.
According to TipRanks, Takkinen is a 2-star analyst with an average return of 0.9% and a 40.98% success rate. Takkinen covers the Healthcare sector, focusing on stocks such as ClearPoint Neuro, Silk Road Medical, and Inotiv.
LENSAR has an analyst consensus of Moderate Buy, with a price target consensus of $8.00.
The company has a one-year high of $5.30 and a one-year low of $1.80. Currently, LENSAR has an average volume of 44.07K.
TipRanks has tracked 36,000 company insiders and found that a few of them are better than others when it comes to timing their transactions. See which 3 stocks are most likely to make moves following their insider activities.
LENSAR (LNSR) Company Description:
LENSAR Inc is a commercial-stage medical device company focused on designing, developing and marketing an advanced femtosecond laser system for the treatment of cataracts.
